Key changes to revised formulary section - eye
Section 2 Cardiovascular
Vasodilator antihypertensive drugs
- minoxidil, sodium nitroprusside. Centrally acting
Calcium Channel Blockers - Dihydropyridines -
Inotropic Sympathomimetics -
Bile acid sequestrants
Dabigatran etexilate (Pradaxa®).
Restricted use for the prevention of stroke and
systemic embolism in adult patients with non-valvular atrial fibrillation with one or
more risk factors. Restricted to patients in whom there is poor INR control with
warfarin unrelated to compliance or in patients who are genuinely intolerant of
Section 3 Respiratory
SABA choice - terbutaline removed. LABAs - Indacaterol moved to restricted list.
Cromoglicate and related therapy - no products recommended. Sodium cromoglicate, nedocromil sodium removed. Leukotriene receptor antagonists - zafirlukast removed.
Allergen immunotherapy - Omalizumab moved to restricted list. Respiratory stimulants and pulmonary surfactants moved to the restricted list.
Section 4 CNS
Sibutramine for treatment of obesity. Marketing authorisation suspended due to risk of cardiovascular adverse effects.
Instanyl® nasal spray. Preferred nasal spray formulation is PecFent®
Section 5 Infections
-Tazocin® (replaced with generic name). Cephalosporins
- Cefaclor and cefuroxime for general use in primary care.
- Flucytosine HIV Infection
Statement stating Famciclovir is not approved for genital herpes.
CMV Infection -
- Ribavarin Antimalarials -
In combination with other anti-retroviral medicinal products for the
treatment of human immunodeficiency virus (HIV-1) infection in adult patients.
Section 6 Endocrine System
Vildagliptin (Galvus®). Treatment of type 2 diabetes mellitus in combination with metformin. Replaced by saxagliptin.
Rosiglitazone (Avandia®, Avandamet®). Treatment of type 2 diabetes mellitus.
Marketing authorisation suspended due to risk of cardiovascular adverse effects.
Section 7 Obstetrics, gynaecology and urinary tract disorders
Implanon® Contraceptive Implant. Replaced by Nexplanon®.
Section 9 Nutrition and Blood
Calcichew-D3®, Calfovit®, Calceos® Calcium and vitamin D preparations. Formulary choice for all formulations is Adcal-D3 range.
Section 10 Musculoskeletal
Coxibs - no longer recommended as formulary choices for any group of patients. Only to be used when at least 2 standard NSAIDs have been ineffective / not tolerated.
Topicasl NSAIDs - ketoprofen, Algesal, Movelat, Transvasin.
Section 11 Eye
Removal of non-specific second line agents i.e. gentamicin, polyfax, propamidine
Corticosteroids - Removed statement about prescribing in primary care on acute prescription only and reviewing every 2 months. Mydriatics - Removed homatropine as antimuscarinic choice
Beta-blockers - removed carteolol, levobunolol
Peri-operative preps. - Removal of flurbiprofen, acetylcholine chloride, apraclonidine. AMD - Removal of pegaptinib
Section 12 ENT
Fluticasone propionate nasal spray. Triamcinolone nasal spray Azelastine nasal spray Budesonide nasal spray
Adcortyl in Orabase Amphoteracin lozenges
Section 13 Skin
Medium weight emollients - Calmurid, Hydromol cream, Unguentum M
Bath additives - Aveeno, Hydromol. Barrier preps. - Epaderm
Rosacea Oral choices - Lymecycline, minocycline
Camouflagers - Covermark Cocois scalp ointment
Product Name: Guardian Complete Worming Chews This revision issued: August, 2011 Page: 1 of 5 Section 1 - Identification of The Material and Supplier Issued by: Intervet Australia Pty Limited (known as MSD Animal Health) 91-105 Harpin Street Tel: 1 800 033 461 (Business hours) Bendigo East, Vic 3550, AUSTRALIA Fax: 1 800 817 414 Company ABN: 79 008 467
Beter effect antidepressiva Suppletie foliumzuur bij gebruik fluoxetine door Ary van der Kuy, Lan Kiauw de Munck-Khoe - 05-10-2012 Foliumzuur verbetert vaak de respons op fluoxetine en andere antidepressiva bij therapieresistente patiënten. Foliumzuur is nodig voor de synthese van monoamine-neurotransmitters. • Casus Een 54-jarige man met de diagnose ernstige depressie, zonder p